Bexson Biomedical Receives FDA Guidance On Developing Wearable Ketamine For Pain, Now Expanding To Treat Major Depression

Bexson Biomedical, Inc. received pre-IND guidance from the U.S. Food and Drug Administration (FDA) for its lead ketamine compound for acute pain management, and is now expanding its ketamine development program to address mental health conditions such as treatment resistant depression and suicidality. Bexson's patented formulation, BB106, is a ketamine therapy delivered via a wearable, subcutaneous patch pump, in development with leading medical device manufacturer, Stevanato Group. Future clinical trials will test the effect of this drug-device combination in acute pain management as an alternative to opioid pain medications, or as an added therapy to lower . . .